Clinical-stage biopharmaceutical company CymaBay Therapeutics, Inc. is dedicated to the development of therapies for treating liver and chronic diseases. Its lead product candidate, seladelpar (MBX-8025), is a selective agonist of peroxisome proliferator activated receptor delta designed to tackle autoimmune liver disease and primary biliary cholangitis (PBC). CymaBay also specializes in the creation of MBX-2982, a treatment for hypoglycemia in type 1 diabetics. With a license agreement secured with ABW Cyclops SPV LP to support the development of seladelpar for PBC treatment, as well as a worldwide license obtained from Janssen Pharmaceuticals, Inc. for the development and commercialization of compounds targeting an undisclosed metabolic disease, the company is making strides in its mission. Originally known as Metabolex, Inc., CymaBay Therapeutics, Inc. has been in operation since 1988 and is headquartered in Newark, California.